To investigate the clinical efficacy of Qili Qiangxin capsules combined with tolvaptan in the treatment of chronic heart failure(CHF) and its effects on serum N-terminal pro-brain natriuretic peptide(NT-proBNP)and high-sensitivity troponin T(hsTnT) levels.
A total of 118 CHF patients treated in our hospital were selected,and the patients were divided into the western medicine group and the Chinese and western medicine group using a simple sorting randomization scheme, with 59 cases in each group. The western medicine group received tolvaptan orally, the Chinese and western medicine group received tolvaptan orally combined with Qili Qiangxin capsules. The therapeutic effects and traditional Chinese medicine(TCM) syndrome scores of two groups were compared. The serum NT-proBNP,hsTnT, and heart function related indicators were detected in both groups before and after treatment, and the incidence of adverse reactions during treatment in both groups were recorded and statistically analyzed.
The total effective rate in the Chinese and western medicine group was higher than the western medicine group(89.83% vs. 74.58%, P<0.05). After treatment, the TCM syndrome scores, serum NT-proBNP, hsTnT, left ventricular end systolic diameter, and left ventricular end diastolic diameter in both groups were decreased compared to before treatment, and the Chinese and western group was lower than those in the western medicine group(P<0.05). After treatment, the left ventricular ejection fraction in both groups was increased compared to before treatment, and the Chinese and western group was higher than that in the western medicine group(P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(15.25% vs. 8.47%, P>0.05).
Qili Qiangxin capsules combined with tolvaptan can produce good clinical efficacy in the treatment of CHF patients, which can greatly improve TCM syndrome,reduce serum NT-proBNP and hsTnT levels, effectively inhibit myocardial injury, improve heart function, and has a high safety.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |